Three compounds advanced into clinical clinical testing in the past eighteen months through our collaborations with other companies:

• SAR3419 – This TAP compound was licensed to sanofi-aventis in 2003 from our preclinical pipeline. It targets CD19, which is found on a number of B-cell cancers including non-Hodgkin’s lymphoma. This compound advanced into clinical testing in October 2007. The first SAR3419 clinical findings are expected to be reported in 2009.

• BIIB015 – Our collaborator Biogen Idec is developing this Cripto-targeting TAP compound for the treatment of solid tumors. Biogen Idec submitted the BIIB015 IND in early 2008 and initiated Phase I testing in mid-2008.

BT-062 – Our collaborator Biotest is developing this TAP compound for the treatment of multiple myeloma. It, too, began Phase I testing during the summer of 2008. We have the right to opt-in on US development and commercialization of BT-062 during its clinical development.

Information on other potential collaboration compounds that has been disclosed includes:

• Genentech has taken exclusive licenses to use our TAP technology with therapeutic antibodies to four undisclosed targets in addition to their license for HER2, and also has certain rights to take licenses to use our technology with antibodies to specific additional targets on agreed-upon terms. The most recent one was licensed in December 2008.



• Two additional compounds - SAR566658 and SAR650984 - have been disclosed in our collaboration with sanofi-aventis. SAR566658 is a TAP compound for the treatment of breast and ovarian cancers and other solid tumors, and SAR650984 is a naked antibody for hematological malignancies.



• In October 2008, Bayer HealthCare licensed rights to use our TAP technology to develop anticancer products targeting an antigen found on solid tumors.

Research on additional compounds is underway through both our own programs and those of current and potential ImmunoGen collaborators.

Back to Pipeline